Xention Siphons Off OAB Therapy Into New Spin Out, Provesica
This article was originally published in The Pink Sheet Daily
Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica
You may also be interested in...
U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation
First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.
PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy
The $170 million up-front that Abbott Laboratories ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down-payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.